Olema Pharmaceuticals (OLMA) Total Current Liabilities (2020 - 2026)
Olema Pharmaceuticals (OLMA) has 7 years of Total Current Liabilities data on record, last reported at $47.2 million in Q1 2026.
- On a quarterly basis, Total Current Liabilities rose 80.97% to $47.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $47.2 million, a 80.97% increase, with the full-year FY2025 number at $51.8 million, up 24.05% from a year prior.
- Total Current Liabilities reached $47.2 million in Q1 2026 per OLMA's latest filing, down from $51.8 million in the prior quarter.
- Over the last five years, Total Current Liabilities for OLMA hit a ceiling of $51.8 million in Q4 2025 and a floor of $10.2 million in Q1 2022.
- A 5-year average of $26.4 million and a median of $26.1 million in 2025 define the central range for Total Current Liabilities.
- Peak YoY movement for Total Current Liabilities: skyrocketed 93.14% in 2024, then fell 0.61% in 2025.
- Tracing OLMA's Total Current Liabilities over 5 years: stood at $16.5 million in 2022, then soared by 30.65% to $21.6 million in 2023, then surged by 93.14% to $41.8 million in 2024, then increased by 24.05% to $51.8 million in 2025, then dropped by 8.95% to $47.2 million in 2026.
- Business Quant data shows Total Current Liabilities for OLMA at $47.2 million in Q1 2026, $51.8 million in Q4 2025, and $41.7 million in Q3 2025.